Enzeshu® is the commercial brand name of Suvemcitug for Injection, a fully human monoclonal antibody developed by Simcere Pharmaceutical. It targets IL-4Rα, blocking the signaling of IL‑4 and IL‑13, two key type 2 inflammatory cytokines, thereby suppressing type 2 inflammatory responses.
Main Indications
Treatment of adult patients with moderate-to-severe atopic dermatitis who have an inadequate response to systemic therapy.
Clinical Research
The pivotal Phase III clinical study conducted in China demonstrated that suvemcitug achieves significant improvements in EASI score and pruritus relief compared with placebo, with a well-tolerated safety profile;
Dose-finding studies confirmed the efficacy of the selected dose regimen in reducing skin inflammation;
Long-term extension trials sustained the clinical benefit without emerging new safety concerns.
Common Side Effects
Severe but important risks: Severe hypersensitivity reactions, parasitic infection, keratitis;
Common mild adverse reactions: Nasopharyngitis, headache, injection site reactions, oral herpes and conjunctivitis.
Approval Status in China
Original drug Enzeshu® (Suvemcitug for Injection, specification:50mg per vial) was officially approved for marketing in China in 2024. It is currently a prescription biologic agent.
Buy Enzeshu (Suvemcitug for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
